Tolerability of central nervous system symptoms among HIV-1 infected efavirenz users: analysis of patient electronic medical record data

References

• Bristol-Myers Squibb. (2016, October). Highlights of prescribing information for Sustiva® (efavirenz). Retrieved from http://packageinserts.bms.com/pi/pi_sustiva.pdf
   Google Scholar
• Centers for Disease Control and Prevention. (2012a). Monitoring selected national HIV prevention and care objectives by using HIV surveillance data – United States and 6 U.S. Dependent areas – 2010. HIV Surveillance Supplemental Report, 17(3 part A).
   Google Scholar
• Centers for Disease Control and Prevention. (2012b, December). CDC fact sheet: New HIV infections in the United States. Retrieved November 30, 2015, from http://www.cdc.gov/nchhstp/newsroom/docs/2012/HIV-Infections-2007-2010.pdf
   Google Scholar
• Centers for Disease Control and Prevention. (2008, December 5). Morbidity and Mortality Weekly Report Recommendations and Reports Appendix A: AIDS-defining conditions. Retrieved November 6, 2015, from http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5710a2.htm
   Google Scholar
• Centers for Disease Control and Prevention. (2014, November). Monitoring selected national HIV prevention and care objectives by using HIV surveillance data – United States and 6 dependent areas – 2012. HIV Surveillance Supplemental Report, 19(3).
   Google Scholar
• Centers for Disease Control and Prevention. (2015). HIV Surveillance Report, 2013 (Vol. 25). Retrieved from http://www.cdc.gov/hiv/library/reports/surveillance/
   Google Scholar
• Cohen, C., Molina, J., Cahn, P., Clotet, B., Fourie, J., Grinsztejn, B., … Boven, K. (2010). Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patients. Journal of the International AIDS Society, 13(Suppl 4), O48. doi:10.1186/1758-2652-13-S4-O48
   PubMedGoogle Scholar
• Elzi, L., Marzolini, C., Furrer, H., Ledergerber, B., Cavassini, M., Hirschel, B., … Swiss HIV Cohort Study. (2010). Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Archives of Internal Medicine, 170(1), 57–65. doi:10.1001/archinternmed.2009.432
   PubMed Web of Science ®Google Scholar
• Ford, N., Shubber, Z., Pozniak, A., Vitoria, M., Doherty, M., Kirby, C., & Calmy, A. (2015). Comparative safety and neuropsychiatric adverse events associated with efavirenz use in first-line antiretroviral therapy: A systematic review and meta-analysis of randomized trials. Journal of Acquired Immune Deficiency Syndromes (1999). doi:10.1097/QAI.0000000000000606
   PubMed Web of Science ®Google Scholar
• Gallant, J., Hardy, D., Bredeek, F., Workowski, K., Towner, W., Dau, L., … Szwarcberg, J. (2013). Elvitegravir/cobicistat/emtricitabine/tenofovir DF (E/C/F/TDF) demonstrates comparable efficacy and favorable tolerability to efavirenz (EFV)/FTC/TDF and to ritonavir-boosted atazanavir (ATV+RTV) plus FTC/TDF in subjects 50 years and older at week 96. Presented at the ICAAC, Denver, Colorado
   Google Scholar
• Kenedi, C. A., & Goforth, H. W. (2011). A systematic review of the psychiatric side-effects of efavirenz. AIDS and Behavior, 15(8), 1803–1818. doi:10.1007/s10461-011-9939-5
   PubMed Web of Science ®Google Scholar
• Leutscher, P. D. C., Stecher, C., Storgaard, M., & Larsen, C. S. (2013). Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects. Scandinavian Journal of Infectious Diseases, 45(8), 645–651. doi:10.3109/00365548.2013.773067
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. (2013, September 9). HIV medication adherence|HIV/AIDS fact sheets|education materials. Retrieved December 27, 2013, from https://aidsinfo.nih.gov/education-materials/fact-sheets/21/54/hiv-medication-adherence
   Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. (2003, November 10). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (pp. 1–239). Department of Health and Human Services. Retrieved from https://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL11102003004.pdf
   Google Scholar
• Pérez-Molina, J. A. (2002). Safety and tolerance of efavirenz in different antiretroviral regimens: Results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clinical Trials, 3(4), 279–286. doi:10.1310/hct.2002.3.4.003
   PubMedGoogle Scholar
• Samji, H., Cescon, A., Hogg, R. S., Modur, S. P., Althoff, K. N., Buchacz, K., … for The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA. (2013). Closing the gap: Increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One, 8(12), e81355. doi:10.1371/journal.pone.0081355
   PubMed Web of Science ®Google Scholar
• Shalit, P., Gallant, J., Mills, A., Crofoot, G., Nguyen, T., Liu, H., … Szwarberg, J. (2013). Long-term tolerability of elvitegravir/cobicistat/emtricitabine/tenofovir DF compared to efavirenz/emtricitabine/tenofovir DF or ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF in treatment-naive HIV-1-infected subjects. Presented at the ICAAC, Denver, Colorado
   Google Scholar
• U.S. Food and Drug Administration. (2006, July 12). 2006 – FDA approves the first once-a day three-drug combination tablet for treatment of HIV-1 [WebContent]. Retrieved October 21, 2013, from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108689.htm
   Google Scholar
• Wohl, D., Cohen, C., Gallant, J., Mills, A., Sax, P., DeJesus, E., … Szwarcberg, J. (2013). Elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB) has durable efficacy and differentiated long-term safety and tolerability versus efavirenz/emtricitabine/tenofovir DF (ATR) at week 144 in treatment-naive HIV patients. Presented at the ICAAC, Denver, Colorado
   Google Scholar